<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1134-8046</journal-id>
<journal-title><![CDATA[Revista de la Sociedad Española del Dolor]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Soc. Esp. Dolor]]></abbrev-journal-title>
<issn>1134-8046</issn>
<publisher>
<publisher-name><![CDATA[Inspira Network Group, S.L ]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1134-80462020000300006</article-id>
<article-id pub-id-type="doi">10.20986/resed.2020.3771/2019</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Características de los pacientes con dolor musculoesquelético moderado a intenso, tratados con comprimidos bucodispersables de paracetamol 325 mg/tramadol HCI 37,5 mg (Paxiflas®) respecto a otras formas orales de la misma combinación. Estudio PROPAX]]></article-title>
<article-title xml:lang="en"><![CDATA[Characteristics of patients suffering mild to severe pain treated with orodispersible tablets of paracetamol 325 mg/tramadol HCL 37,5mg (Paxiflas®) in comparison with other oral formulations containing the same combination. PROPAX study]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aguilar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aranda]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Teknon-Quirón Servicio de Traumatología ]]></institution>
<addr-line><![CDATA[Barcelona ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Laboratorios Gebro Pharma  ]]></institution>
<addr-line><![CDATA[Barcelona ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<volume>27</volume>
<numero>3</numero>
<fpage>168</fpage>
<lpage>177</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1134-80462020000300006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1134-80462020000300006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1134-80462020000300006&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Objetivo: Comparar el perfil del paciente con dolor musculoesquelético moderado a intenso en tratamiento con los comprimidos bucodispersables, Paxiflas® [tramadol HCl (37,5 mg) y paracetamol (325 mg)] respecto a otras combinaciones de tramadol HCl (37,5 mg) y paracetamol (325 mg). Secundariamente, se comparó la adherencia, satisfacción y preferencia entre grupos.  Materiales y métodos: El estudio Propax es un estudio postautorización, observacional, transversal, retrospectivo y multicéntrico. La variable principal fue el perfil sociodemográfico y clínico del paciente. La satisfacción de los pacientes en tratamiento se midió mediante el cuestionario genérico SATMED-Q; la adherencia, con el cuestionario Morisky-Green; y la preferencia, mediante una batería de preguntas con respuesta tipo Likert.  Resultados: Se evaluaron 835 pacientes. No se observaron diferencias estadísticamente significativas en el perfil clínico y sociodemográfico de los pacientes entre ambos grupos de tratamiento, pero sí entre los pacientes en tratamiento con Paxiflas®, en relación con la evaluación de la satisfacción, tanto en la puntuación total (p = 0,002) como en las dimensiones: la interferencia de los efectos secundarios de la medicación en las actividades cotidianas (p = 0,006), la comodidad de uso (p &lt; 0,001) y la opinión general respecto a la medicación y su estado de salud (p = 0,010). Además, la preferencia de los pacientes por el tratamiento con Paxiflas® fue estadísticamente significativas (p &lt; 0,001) en comparación con otras combinaciones orales de tramadol HCI (37,5 mg) y paracetamol (325 mg), incluyendo la percepción de rapidez en el alivio del dolor, comodidad de la medicación, sabor y sensación agradable, conveniencia del tamaño del comprimido, y elección final del tratamiento.  Conclusiones: Entre los distintos grupos de tratamiento no se encontraron diferencias estadísticamente significativas en el perfil de los pacientes, ni en el grado de adherencia a la medicación. Los comprimidos bucodispersables Paxiflas® han demostrado un mayor grado de satisfacción y preferencia por parte de los pacientes con dolor musculoesquelético agudo y crónico moderado e intenso frente a otras formas orales.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Objective: To compare profiles of patients suffering mild to severe pain treated with orodispersible formulation of paracetamol 325 mg/tramadol HCL 37,5mg (Paxiflas®) in comparison with other oral formulations of paracetamol 325 mg/tramadol HCL 37,5mg. In addition, to compare adherence, satisfaction and preference between groups.  Materials and methods: Propax is a postautorization, observational, cross-sectional retrospective and multicentre study. The primary variable was the clinic and sociodemographic profile of the patient. Patient satisfaction was measured by STAMED generic questionnaire; adherence was measured by Morisky-Green questionnaire and preference was measured using a battery of questions with Likert-like answer.  Results: A number 835 patients were evaluated. Clinical and sociodemographic statistically significant differences were not observed between both groups of patients. However, there were statistically significant differences among Paxiflas® group of patients in satisfaction assessment, in both total score (p = 0,002) and dimensions: side effects interferences in everyday life (p = 0,006), convenience and ease of use (p &lt; 0,001) and overall opinion of medication and health condition (p = 0,010). In addition, patient preference of Paxiflas® over other oral combinations of tramadol HCI (37.5 mg) and paracetamol (325 mg) was statistically significant (p &lt; 0,001), including perception of pain relief speed, medication convenience, taste and likeable sensation, tablet size convenience and final election of treatment.  Conclusions: Statistically significant differences were not observed in neither patient profile nor adherence. Paxiflas® orodispersible tablets demonstrated to provide greater satisfaction and preference among patients suffering acute and mild chronic musculoskeletal pain than other oral formulations.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Musculoskeletal pain]]></kwd>
<kwd lng="en"><![CDATA[tramadol/paracetamol]]></kwd>
<kwd lng="en"><![CDATA[orodispersible tablets]]></kwd>
<kwd lng="en"><![CDATA[satisfaction]]></kwd>
<kwd lng="en"><![CDATA[adherence]]></kwd>
<kwd lng="en"><![CDATA[preference]]></kwd>
<kwd lng="es"><![CDATA[Dolor musculoesquelético]]></kwd>
<kwd lng="es"><![CDATA[tramadol/paracetamol]]></kwd>
<kwd lng="es"><![CDATA[comprimidos bucodispersables]]></kwd>
<kwd lng="es"><![CDATA[satisfacción]]></kwd>
<kwd lng="es"><![CDATA[adherencia]]></kwd>
<kwd lng="es"><![CDATA[preferencia]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<collab>Lancet</collab>
<article-title xml:lang=""><![CDATA[Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2017</year>
<volume>390</volume>
<numero>10100</numero>
<issue>10100</issue>
<page-range>1211-59</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McDonald]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[DiBonaventura]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ullman]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Musculoskeletal pain in the workforce: the effects of back, arthritis, and fibromyalgia pain on quality of life and work productivity]]></article-title>
<source><![CDATA[J Occup Environ Med]]></source>
<year>2011</year>
<volume>53</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>765-70</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hoy]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Cross]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vos]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Naghavi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Buchbinder]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The global burden of other musculoskeletal disorders: estimates from the Global Burden of Disease 2010 study]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2014</year>
<volume>73</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1462-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<collab>Ministerio de Sanidad CyBSGdE</collab>
<source><![CDATA[Encuesta Nacional de Salud España 2017]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Ministerio de Sanidad CyBSGdE]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Langley]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The prevalence, correlates and treatment of pain in the European Union]]></article-title>
<source><![CDATA[Curr Med Res Opin]]></source>
<year>2011</year>
<volume>27</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>463-80</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Langley]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz-Iban]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Andres]]></surname>
<given-names><![CDATA[J De]]></given-names>
</name>
<name>
<surname><![CDATA[Castellon]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The prevalence, correlates and treatment of pain in Spain]]></article-title>
<source><![CDATA[J Med Econ]]></source>
<year>2011</year>
<volume>14</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>367-80</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Catala]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Reig]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Artes]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Aliaga]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Segu]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of pain in the Spanish population: telephone survey in 5000 homes]]></article-title>
<source><![CDATA[Eur J Pain]]></source>
<year>2002</year>
<volume>6</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>133-40</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<source><![CDATA[WHO's pain ladder]]></source>
<year>2012</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raffa]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacology of oral combination analgesics: rational therapy for pain]]></article-title>
<source><![CDATA[J Clin Pharm Ther]]></source>
<year>2001</year>
<volume>26</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>257-64</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rawal]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Macquaire]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Catala]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Berti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Wietlisbach]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tramadol/paracetamol combination tablet for postoperative pain following ambulatory hand surgery: a double-blind, double-dummy, randomized, parallel-group trial]]></article-title>
<source><![CDATA[J Pain Res]]></source>
<year>2011</year>
<volume>4</volume>
<page-range>103-10</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raffa]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Friderichs]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Reimann]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Shank]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Codd]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
<name>
<surname><![CDATA[Vaught]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic]]></article-title>
<source><![CDATA[J Pharmacol Exp Ther]]></source>
<year>1992</year>
<volume>260</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>275-85</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McClellan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tramadol/paracetamol]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2003</year>
<volume>63</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1079-86</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Potential analgesic mechanisms of acetaminophen]]></article-title>
<source><![CDATA[Pain Physician]]></source>
<year>2009</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>269-80</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mejjad]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Serrie]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ganry]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiological data, efficacy and safety of a paracetamol-tramadol fixed combination in the treatment of moderate-to-severe pain SALZA: a post-marketing study in general practice]]></article-title>
<source><![CDATA[Curr Med Res Opin]]></source>
<year>2011</year>
<volume>27</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1013-20</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schug]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combination analgesia in 2005 - a rational approach: focus on paracetamol-tramadol]]></article-title>
<source><![CDATA[Clin Rheumatol]]></source>
<year>2006</year>
<volume>25</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>S16-21</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peloso]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Fortin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Beaulieu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kamin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenthal]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analgesic efficacy and safety of tramadol/ acetaminophen combination tablets (Ultracet) in treatment of chronic low back pain: a multicenter, outpatient, randomized, double blind, placebo controlled trial]]></article-title>
<source><![CDATA[J Rheumatol]]></source>
<year>2004</year>
<volume>31</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2454-63</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silverfield]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Kamin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenthal]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tramadol/acetaminophen combination tablets for the treatment of osteoarthritis flare pain: a multicenter, outpatient, randomized, double-blind, placebo-controlled, parallel-group, add-on study]]></article-title>
<source><![CDATA[Clin Ther]]></source>
<year>2002</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>282-97</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mullican]]></surname>
<given-names><![CDATA[WS]]></given-names>
</name>
<name>
<surname><![CDATA[Lacy]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tramadol/acetaminophen combination tablets and codeine/acetaminophen combination capsules for the management of chronic pain: a comparative trial]]></article-title>
<source><![CDATA[Clin Ther]]></source>
<year>2001</year>
<volume>23</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1429-45</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Emkey]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenthal]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Jordan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kamin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial]]></article-title>
<source><![CDATA[J Rheumatol]]></source>
<year>2004</year>
<volume>31</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>150-6</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="">
<source><![CDATA[Postoperative Pain Management- Good Clinical Practice. General recommendations and principles for succesful pain management]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dhillon]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tramadol/paracetamol fixed-dose combination: a review of its use in the management of moderate to severe pain]]></article-title>
<source><![CDATA[Clin Drug Investig]]></source>
<year>2010</year>
<volume>30</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>711-38</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="book">
<collab>Ministerio de Sanidad, Servicios Sociales e Igualdad</collab>
<source><![CDATA[Informe de Utilización de Medicamentos. Utilización de medicamentos opioides en España durante el periodo 2008-2015]]></source>
<year>2017</year>
<publisher-name><![CDATA[Ministerio de Sanidad, Servicios Sociales e Igualdad. Agencia Española de Medicamentos y Productos Sanitarios]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Markotic]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Cerni Obrdalj]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Zalihic]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pehar]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hadziosmanovic]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Pivic]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adherence to pharmacological treatment of chronic nonmalignant pain in individuals aged 65 and older]]></article-title>
<source><![CDATA[Pain Med]]></source>
<year>2013</year>
<volume>14</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>247-56</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Broekmans]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dobbels]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Milisen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Morlion]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Vanderschueren]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Determinants of medication underuse and medication overuse in patients with chronic non-malignant pain: a multicenter study]]></article-title>
<source><![CDATA[Int J Nurs Stud]]></source>
<year>2010</year>
<volume>47</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1408-17</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernandes Tavares]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Espada García]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Martín Sabroso]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gil Alegre]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Torres Suárez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comprimidos bucodispersables: ventajas terapéuticas y tecnológicas de elaboración]]></article-title>
<source><![CDATA[Ars Pharmaceutica J]]></source>
<year>2009</year>
<volume>50</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="book">
<collab>Sanitarios AEdMyP</collab>
<source><![CDATA[Ficha Técnica Paxiflas 7,5 mg/325 mg comprimidos bucodispersables EFG]]></source>
<year>2016</year>
<publisher-name><![CDATA[Sanitarios AEdMyP]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tornero]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cervera]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Godoy]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Boyer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Valls]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Paxiflas®: Nueva combinación bucodispersable de tramadol/paracetamolv para el tratamiento del dolor moderado a intenso]]></article-title>
<source><![CDATA[Rev Soc Esp Dolor]]></source>
<year>2017</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>59-67</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aliaga]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Nebreda]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ojeda]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Molà]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Galván]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudio observacional para conocer el perfil de los pacientes con dolor crónico musculoesquelético en tratamiento con la combinación de Tramadol 37,5 mg/Paracetamol 325 mg o Paracetamol 1 g o Metamizol 575 mg (estudio PROFILE)]]></article-title>
<source><![CDATA[Rev Soc Esp Dolor]]></source>
<year>2013</year>
<volume>20</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>122-31</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="">
<source><![CDATA[Guidance for Industry]]></source>
<year>2003</year>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruiz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Pardo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rejas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Soto]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Villasante]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Aranguren]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development and validation of the "Treatment Satisfaction with Medicines Questionnaire" (SATMED-Q)]]></article-title>
<source><![CDATA[Value Health]]></source>
<year>2008</year>
<volume>11</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>913-26</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morisky]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[LW]]></given-names>
</name>
<name>
<surname><![CDATA[Levine]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Concurrent and predictive validity of a self-reported measure of medication adherence]]></article-title>
<source><![CDATA[Med Care]]></source>
<year>1986</year>
<volume>24</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>67-74</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Herdman]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
</person-group>
<collab>Salud LIdRe</collab>
<source><![CDATA[La medida de la satisfacción con el tratamiento en la Investigacion de Resultados en Salud]]></source>
<year>2000</year>
<page-range>79-93</page-range><publisher-loc><![CDATA[Barcelona ]]></publisher-loc>
<publisher-name><![CDATA[Edimac]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spilker]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Methods of Assessing and Improving Patient Compliance in Clinical Trials]]></article-title>
<source><![CDATA[IRB: Ethics &amp; Human Research]]></source>
<year>1992</year>
<volume>14</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Uko-Ekpenyong]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improving medication adherence with orally disintegrating tablets]]></article-title>
<source><![CDATA[Nursing]]></source>
<year>2006</year>
<volume>36</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>20-1</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
